The global microcrystalline cellulose market revenue is expected to register a moderate CAGR over the forecast period. The global microcrystalline cellulose market report has been segmented on the source type, end use industry, and region.

Based on source type, the global microcrystalline cellulose market is segmented based on wood based, and non-wood based. The wood based segment accounted for significant revenue share of the market and is expected to register a CAGR of XX.X%.

Based on end-use industry, the target market is segmented based on pharmaceutical, food & beverages, and cosmetics & personal care. The pharmaceutical segment accounted for major revenue share in 2017 and is expected to maintain its dominance over the forecast period. Increasing demand for microcrystalline cellulose in pharmaceutical industry for manufacturing solid dosage form is major factor expected to drive growth of this segment over the forecast period.

Request for the Sample Report Here: https://marketresearch.biz/report/microcrystalline-cellulose-market/request-sample/

Regional segmentation includes North America, Europe, Latin America, Asia Pacific and Middle East and Africa. North America contributes major share in terms of revenue in global microcrystalline cellulose market and is expected to maintain its dominance over the forecast period. Market in Asia Pacific is expected to register highest growth over the forecast period. Increasing demand for microcrystalline cellulose in countries such as China and India, owing to increasing number pharmaceutical industries coupled rising public and private investments in this sector are major factors expected to drive growth of market in the region over the forecast period.

Some prominent players in the global microcrystalline cellulose market are FMC Corporation, E.I. Du Pont De Nemours and Companies, Asahi Kasei Corporation, Tembec Inc., DFE Pharma, Blanver Farmoquimica Ltd., JRS Pharma, Avantor Performance Materials, Inc., Mingtai Chemical Co., Ltd., and Pharmatrans-Sanaq AG